Iris BioTechnologies (OTCMKTS:IRSB) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for disorders of bone and mineral metabolism. The company’s research is centered on selective activators of TRPV5 and TRPV6 calcium channels, aiming to address conditions such as osteoporosis, hypercalciuria and kidney stones. By modulating calcium transport pathways, Iris BioTechnologies seeks to provide targeted treatments that improve bone density and reduce urinary calcium losses.
Founded in 2018 and headquartered in Irvine, California, Iris BioTechnologies has built a multidisciplinary team of scientists specializing in ion channel biology, medicinal chemistry and translational medicine. Its lead candidate, IBS-101, is currently in preclinical development with an emphasis on safety and efficacy in models of postmenopausal bone loss. The company also maintains collaborations with academic laboratories in North America and Asia to advance its understanding of calcium homeostasis and to accelerate the development of its pipeline.
In addition to its core R&D activities, Iris BioTechnologies has established strategic partnerships with contract research organizations for toxicology and formulation studies, and it engages regulatory consultants to prepare for future clinical trials. The company’s integrated approach combines computational drug design, high-throughput screening and in vivo validation to streamline candidate selection and optimize pharmacological profiles.
Leadership at Iris BioTechnologies is composed of industry veterans with extensive experience in biopharmaceutical development. The executive team is led by Chief Executive Officer Dr. Zara Miller, a former director of ion channel research at a global pharmaceutical firm, and Chief Scientific Officer Dr. Frank Delgado, a recognized expert in calcium channel physiology. Guided by a board of directors with backgrounds in venture capital, clinical development and regulatory affairs, Iris BioTechnologies is advancing toward its goal of bringing first-in-class therapies to patients suffering from debilitating bone and mineral disorders.
AI Generated. May Contain Errors.
Free IRSB Stock Alerts